Home
Home

eteplirsen

Sarepta Therapeutics: Irrational Exuberance

Sarepta Therapeutics: Irrational Exuberance
Seeking Alpha

FDA Says, "Call Me Maybe"

FDA Says, "Call Me Maybe"
Motley Fool

2 Views on Sarepta's FDA News

2 Views on Sarepta's FDA News
Motley Fool

Sarepta tumbles after FDA requests more data on drug

Sarepta tumbles after FDA requests more data on drug
The Fly on the Wall

Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug

Sarepta Fans: A Single Data Slide Raises Questions About Glaxo's DMD Drug
TheStreet.com

Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In

Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In
Seeking Alpha

Glaxo's Drisapersen Data Revealed Early

Glaxo's Drisapersen Data Revealed Early
TheStreet.com

Sarepta-Glaxo Duchenne's Rivalry Heats Up This Week

Sarepta-Glaxo Duchenne's Rivalry Heats Up This Week
TheStreet.com

Sarepta's Eteplirsen Boys Keep On Walking

Sarepta's Eteplirsen Boys Keep On Walking
TheStreet.com

Sarepta set to rise if seeks quick drug OK

Sarepta set to rise if seeks quick drug OK
Reuters